Tim Smith

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.

New data indicates that hospital culture must be considered when facilities make significant changes, especially when they concern institutional values.

New phase 2 data indicates safety and efficacy of dersimelagon, suggesting potential development as an oral treatment for erythropoietic protoporphyria and X-linked protoporphyria.

This new data into alopecia areata patients’ associated conditions may require future research into potential causal relationships with such comorbidities.

New research on patients with pemphigus highlighted the heavy mental burden on those with these conditions and the importance of screening for anxiety, depression, and quality of life.

New research into menopausal hormone therapy shows that even short term use can have downstream consequences for neurological health.

New research into the information needs of adults over 65 and their patient portal interactions points to the value of consumer-oriented health information technologies.

New data drawn from the EUSTAR database made clear several key insights into this subset of systemic sclerosis patients, with survival and skin manifestations being highlighted.

In this Q&A interview with physician assistant Renata Block, Block spoke on some of her thoughts about the recent SDPA conference and its presentations.

This interview featured a discussion with Dr. Mostaghimi, during which he described some of the latest treatments for alopecia, new policies and efforts for patients, and general conference takeaways.

In this interview, physician assistant Hope Cook described some of the major talking points from her conference talk titled ‘Healing PA Burnout.’

In this discussion with HCPLive, Dr. Markowitz spoke about some of the biggest takeaways from her conference presentation on skin cancer treatments.

In this interview, Dr. Noor spoke about the contents of his conference presentation regarding the tailoring of treatment plans to patients with skin of color.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

Describing the biggest takeaways from her talk ‘Diagnosis and Management of Blistering Disorders,’ Dr. Noe went in depth about treatment of blistering in patients.

This interview with Dr. Noe at the SDPA conference featured a discussion about her background and her presentation titled ‘Diagnosis and Management of Blistering Disorders.'

In another interview segment, Dr. Amin described some of the other biggest points from his conference talk on choosing the best route for psoriasis in patients.

In this interview segment, Dr. Amin described some of the major takeaways from his conference talk titled ‘Biological Bootcamp: How to Select the Best Biologics for Your Psoriasis Patient.’

In a conference presentation, Dr. Imadojemu discussed the topic of afro-textured hair and various hair and scalp disorders.

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.

In this interview segment, Dr. Barbieri explained the major takeaways from his conference talk on acne and rosacea with a focus on the more severe levels of these conditions.

In this conference interview, Dr. Barbieri described some of the major takeaways from his talk on foundational tools for patients with acne and rosacea.

During this conference talk, Dr. Nicole Gunasekera spoke about options for acne scar treatments such as chemical peels and microneedling, as well as special considerations for richly-pigmented skin.

In his conference presentation, Dr. Arash Mostaghimi reviewed the ways to ensure access to the right information from a biopsy as well as how to interpret potentially confusing biopsy results.

These new findings suggest the need for expansion of JAK1/JAK2 targeting approaches for treatment of eosinophilic cellulitis and other types of eosinophilic disease.

This new data emphasizes the vital importance of timely detection and effective treatment for squamous cell carcinomas in this particular population.

New data led to positive results for the simple-to-use PEN-FAST tool, allowing its use among allergists and even primary care physicians in cases in which access to allergists is limited.

This new tool, using an automated analysis of different parts of the body, could help clinicians to address previously unmet needs for treatment in conditions such as psoriasis.